CA2867621A1 - Fast diagnosis and personalized treatments for acne - Google Patents
Fast diagnosis and personalized treatments for acne Download PDFInfo
- Publication number
- CA2867621A1 CA2867621A1 CA2867621A CA2867621A CA2867621A1 CA 2867621 A1 CA2867621 A1 CA 2867621A1 CA 2867621 A CA2867621 A CA 2867621A CA 2867621 A CA2867621 A CA 2867621A CA 2867621 A1 CA2867621 A1 CA 2867621A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- acnes
- acne
- strain
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 275
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 270
- 238000011282 treatment Methods 0.000 title claims description 58
- 238000003745 diagnosis Methods 0.000 title description 11
- 238000000034 method Methods 0.000 claims abstract description 128
- 230000008685 targeting Effects 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 150000003384 small molecules Chemical class 0.000 claims abstract description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 9
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 9
- 229960000074 biopharmaceutical Drugs 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 229
- 102000004169 proteins and genes Human genes 0.000 claims description 138
- 108020004414 DNA Proteins 0.000 claims description 86
- 239000000523 sample Substances 0.000 claims description 80
- 241000186427 Cutibacterium acnes Species 0.000 claims description 77
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 76
- 244000005700 microbiome Species 0.000 claims description 72
- 238000012163 sequencing technique Methods 0.000 claims description 42
- 230000001580 bacterial effect Effects 0.000 claims description 35
- 230000037311 normal skin Effects 0.000 claims description 31
- 230000036074 healthy skin Effects 0.000 claims description 27
- 239000000047 product Substances 0.000 claims description 24
- 241001659030 [Propionibacterium] humerusii Species 0.000 claims description 23
- 108020000946 Bacterial DNA Proteins 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 239000006041 probiotic Substances 0.000 claims description 18
- 235000018291 probiotics Nutrition 0.000 claims description 18
- 230000002238 attenuated effect Effects 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 239000002207 metabolite Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000012300 Sequence Analysis Methods 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 156
- 235000018102 proteins Nutrition 0.000 description 132
- 125000006850 spacer group Chemical group 0.000 description 55
- 238000004458 analytical method Methods 0.000 description 52
- 239000002773 nucleotide Substances 0.000 description 50
- 239000013612 plasmid Substances 0.000 description 48
- 125000003729 nucleotide group Chemical group 0.000 description 44
- 201000010099 disease Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 108700026244 Open Reading Frames Proteins 0.000 description 34
- 229940055019 propionibacterium acne Drugs 0.000 description 26
- 230000036541 health Effects 0.000 description 23
- 239000003242 anti bacterial agent Substances 0.000 description 22
- 229940088710 antibiotic agent Drugs 0.000 description 22
- 238000003753 real-time PCR Methods 0.000 description 22
- 230000002068 genetic effect Effects 0.000 description 21
- 241000894007 species Species 0.000 description 21
- 241001515965 unidentified phage Species 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- 101150079601 recA gene Proteins 0.000 description 18
- 244000005714 skin microbiome Species 0.000 description 17
- 230000003321 amplification Effects 0.000 description 16
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 238000010453 CRISPR/Cas method Methods 0.000 description 15
- 230000003115 biocidal effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 15
- 238000009826 distribution Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 244000005702 human microbiome Species 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 241000186429 Propionibacterium Species 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 238000002869 basic local alignment search tool Methods 0.000 description 12
- 230000000813 microbial effect Effects 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 238000007400 DNA extraction Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000012268 genome sequencing Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 238000001066 phage therapy Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 101710115335 Gene 22 protein Proteins 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 210000001331 nose Anatomy 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 230000001018 virulence Effects 0.000 description 10
- 101710125418 Major capsid protein Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000008506 pathogenesis Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 206010034133 Pathogen resistance Diseases 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 101700012268 Holin Proteins 0.000 description 7
- 108090001060 Lipase Proteins 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000036559 skin health Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 241000736262 Microbiota Species 0.000 description 6
- 101710124413 Portal protein Proteins 0.000 description 6
- 101710112672 Probable tape measure protein Proteins 0.000 description 6
- 101710204224 Tape measure protein Proteins 0.000 description 6
- 101710194975 Uncharacterized protein gp14 Proteins 0.000 description 6
- 241000186569 [Clostridium] leptum Species 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000004088 simulation Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108700023418 Amidases Proteins 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 5
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 5
- 241001464975 Cutibacterium granulosum Species 0.000 description 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 5
- 102000004882 Lipase Human genes 0.000 description 5
- 108010055016 Rec A Recombinases Proteins 0.000 description 5
- 108020001027 Ribosomal DNA Proteins 0.000 description 5
- 101710109927 Tail assembly protein GT Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009836 endodontic lesion Effects 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 238000002887 multiple sequence alignment Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 108020004418 ribosomal RNA Proteins 0.000 description 5
- 238000013515 script Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010000503 Acne cystic Diseases 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 241000107405 Cutibacterium acnes KPA171202 Species 0.000 description 4
- 241001635598 Enicostema Species 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000001218 Rec A Recombinases Human genes 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 102000005922 amidase Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 238000003205 genotyping method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229940127234 oral contraceptive Drugs 0.000 description 4
- 239000003539 oral contraceptive agent Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003939 Membrane transport proteins Human genes 0.000 description 3
- 108090000301 Membrane transport proteins Proteins 0.000 description 3
- 241000566145 Otus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000011436 cob Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000011392 neighbor-joining method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000021527 ATP binding proteins Human genes 0.000 description 2
- 108091011108 ATP binding proteins Proteins 0.000 description 2
- 101710146995 Acyl carrier protein Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- 108020004513 Bacterial RNA Proteins 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090001042 Hydro-Lyases Proteins 0.000 description 2
- 102000004867 Hydro-Lyases Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000001337 Mantel test Methods 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 241000485287 Propionibacterium acnes SK137 Species 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 2
- 101150090370 ade4 gene Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940057324 biore Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ORTYMGHCFWKXHO-UHFFFAOYSA-N diethadione Chemical compound CCC1(CC)COC(=O)NC1=O ORTYMGHCFWKXHO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000013081 phylogenetic analysis Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000012070 whole genome sequencing analysis Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- WWYNJERNGUHSAO-CULCCENASA-N (8r,9s,10r,13s,14s)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)(C(CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-CULCCENASA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- 108010028984 3-isopropylmalate dehydratase Proteins 0.000 description 1
- 101710161460 3-oxoacyl-[acyl-carrier-protein] synthase Proteins 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001291962 Actinobaculum Species 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 241000379991 Anaerococcus Species 0.000 description 1
- 241001626813 Anoxybacillus Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100006523 Arabidopsis thaliana CHC2 gene Proteins 0.000 description 1
- 101100016388 Arabidopsis thaliana PAS2 gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101710174771 Baseplate protein gp16 Proteins 0.000 description 1
- 102000011802 Beta-ketoacyl synthases Human genes 0.000 description 1
- 108050002233 Beta-ketoacyl synthases Proteins 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100335054 Caenorhabditis elegans flp-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000202285 Claravis Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001429175 Colitis phage Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 241001528480 Cupriavidus Species 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000006465 DNA Restriction-Modification Enzymes Human genes 0.000 description 1
- 108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 101710200158 DNA packaging protein Proteins 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 241000688137 Diaphorobacter Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101000918259 Enterobacteria phage T4 Exonuclease subunit 1 Proteins 0.000 description 1
- 101000764582 Enterobacteria phage T4 Tape measure protein Proteins 0.000 description 1
- 101100007788 Escherichia coli (strain K12) casA gene Proteins 0.000 description 1
- 101100007792 Escherichia coli (strain K12) casB gene Proteins 0.000 description 1
- 101100219622 Escherichia coli (strain K12) casC gene Proteins 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 101100438439 Escherichia coli (strain K12) ygbT gene Proteins 0.000 description 1
- 101100005249 Escherichia coli (strain K12) ygcB gene Proteins 0.000 description 1
- 101000896152 Escherichia phage Mu Baseplate protein gp47 Proteins 0.000 description 1
- 101000621102 Escherichia phage Mu Portal protein Proteins 0.000 description 1
- 101000830028 Escherichia phage Mu Uncharacterized protein gp25 Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000187809 Frankia Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 102000041143 GNAT family Human genes 0.000 description 1
- 108091061015 GNAT family Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710160913 GemA protein Proteins 0.000 description 1
- 241000193789 Gemella Species 0.000 description 1
- 101710193747 Gene 18 protein Proteins 0.000 description 1
- 101710167068 Gene 20 protein Proteins 0.000 description 1
- 101710171049 Gene 21 protein Proteins 0.000 description 1
- 101710128254 Gene 42 protein Proteins 0.000 description 1
- 101710142014 Gene 46 protein Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101001052021 Haemophilus phage HP1 (strain HP1c1) Probable tail fiber protein Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101001124945 Homo sapiens Pre-mRNA-splicing factor 38A Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 101100297150 Komagataella pastoris PEX3 gene Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108050003365 Malonyl CoA-acyl carrier protein transacylases Proteins 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 101710167711 Minor tail protein Proteins 0.000 description 1
- 238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 1
- 101000808072 Mycobacterium phage L5 Gene 45 protein Proteins 0.000 description 1
- 241001208556 Mycobacterium virus Che9d Species 0.000 description 1
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 description 1
- 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 101100495430 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hH3v gene Proteins 0.000 description 1
- 241001078793 Niastella Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 241000383839 Novosphingobium Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108050005396 Ornithine cyclodeaminase/mu-crystallin Proteins 0.000 description 1
- 102000017356 Ornithine cyclodeaminase/mu-crystallin Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000160321 Parabacteroides Species 0.000 description 1
- 241000372441 Pelomonas Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000056222 Peptide Synthases Human genes 0.000 description 1
- 108700018928 Peptide Synthases Proteins 0.000 description 1
- 241000351207 Peptoniphilus Species 0.000 description 1
- 241001112692 Peptostreptococcaceae Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001135342 Phyllobacterium Species 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- 108050005751 Portal proteins Proteins 0.000 description 1
- 102100029435 Pre-mRNA-splicing factor 38A Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710169056 Protein ParA Proteins 0.000 description 1
- 101000802260 Pseudomonas phage D3112 Anti-CRISPR protein 31 Proteins 0.000 description 1
- 241000186336 Pseudopropionibacterium propionicum Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 101150087119 SAG gene Proteins 0.000 description 1
- 101100136256 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX19 gene Proteins 0.000 description 1
- 101100315760 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX4 gene Proteins 0.000 description 1
- 108050007140 SagB-type dehydrogenase domains Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000854711 Shinkai Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 101710142606 Sliding clamp Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000187759 Streptomyces albus Species 0.000 description 1
- 241001493533 Streptophyta Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101710166729 Tail fiber protein Proteins 0.000 description 1
- 101100329497 Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1) cas2 gene Proteins 0.000 description 1
- 101100273269 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) cse3 gene Proteins 0.000 description 1
- 101710158136 Trans-prenyltransferase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 241001394203 [Clostridium] leptum DSM 753 Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940022824 amnesteem Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 101150000705 cas1 gene Proteins 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 101150055191 cas3 gene Proteins 0.000 description 1
- -1 cas5e Proteins 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940031301 claravis Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 101150067044 copG gene Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 108010066830 dimethyl sulfoxide reductase Proteins 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 108010005965 endoglycoceramidase Proteins 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- VAVAILGEOMLRRK-UHFFFAOYSA-H iron(III) dicitrate(3-) Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VAVAILGEOMLRRK-UHFFFAOYSA-H 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 210000001664 manubrium Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229940007688 norgestimate and ethinylestradiol Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940038309 personalized vaccine Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108090000589 ribonuclease E Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940034345 sotret Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 108010050301 tRNA nucleotidyltransferase Proteins 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000006514 viral protein processing Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612290P | 2012-03-17 | 2012-03-17 | |
| US61/612,290 | 2012-03-17 | ||
| PCT/US2013/032551 WO2013142378A1 (en) | 2012-03-17 | 2013-03-15 | Fast diagnosis and personalized treatments for acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2867621A1 true CA2867621A1 (en) | 2013-09-26 |
Family
ID=49223275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2867621A Abandoned CA2867621A1 (en) | 2012-03-17 | 2013-03-15 | Fast diagnosis and personalized treatments for acne |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20150086581A1 (enExample) |
| EP (3) | EP3692999A1 (enExample) |
| JP (3) | JP2015512255A (enExample) |
| CN (2) | CN110055320A (enExample) |
| AU (3) | AU2013235340B2 (enExample) |
| BR (1) | BR112014023005A2 (enExample) |
| CA (1) | CA2867621A1 (enExample) |
| SG (1) | SG11201405783VA (enExample) |
| WO (1) | WO2013142378A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021016347A1 (en) * | 2019-07-22 | 2021-01-28 | The Regents Of The University Of California | Compositions and methods for treating skin infections and other diseases |
Families Citing this family (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US12533312B2 (en) | 2011-02-04 | 2026-01-27 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP3692999A1 (en) * | 2012-03-17 | 2020-08-12 | The Regents of the University of California | Fast diagnosis and personalized treatments for acne |
| EP3011046A4 (en) | 2013-06-18 | 2017-03-01 | Prodermiq, Inc. | Customized skin care products and personal care products based on the analysis of skin flora |
| US10633714B2 (en) | 2013-07-21 | 2020-04-28 | Pendulum Therapeutics, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| JP2016536021A (ja) | 2013-11-07 | 2016-11-24 | エディタス・メディシン，インコーポレイテッド | ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| EP3139939B1 (en) * | 2014-05-07 | 2023-09-06 | The Regents of The University of California | Compositions and methods for treating skin and mucous membrane diseases |
| CA2950945A1 (en) | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| AU2015308910B2 (en) | 2014-08-27 | 2017-12-07 | Caribou Biosciences, Inc. | Methods for increasing Cas9-mediated engineering efficiency |
| US9703929B2 (en) | 2014-10-21 | 2017-07-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| WO2016168350A1 (en) * | 2015-04-13 | 2016-10-20 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| EP3285872A4 (en) * | 2015-04-20 | 2019-02-20 | S-Biomedic NV | METHOD AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF SKIN MICROBIOMA WITH COMPLEX MIXTURES OF BACTERIAL BARS |
| JP6046849B1 (ja) * | 2015-07-21 | 2016-12-21 | ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 | 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法 |
| AU2016301963A1 (en) | 2015-08-06 | 2018-02-15 | Ares Genetics Gmbh | Genetic resistance prediction against antimicrobial drugs in microorganism using structural changes in the genome |
| WO2017044871A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for eczema |
| EP3346911A4 (en) * | 2015-09-09 | 2019-05-08 | Ubiome Inc. | METHOD AND COMPOSITIONS FOR MICROBIOMA DIAGNOSTICS AND THERAPEUTIC FOR INFECTION DISEASE AND OTHERS SUFFERING TO THE USE OF ANTIBIOTICS |
| CA3006044A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health |
| EP3350761B1 (en) | 2015-09-17 | 2023-12-20 | Prodermiq, Inc. | Predicting skin age based on the analysis of skin flora and lifestyle data |
| EP4434589A3 (en) | 2015-10-23 | 2025-05-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
| JP6872222B2 (ja) * | 2015-11-04 | 2021-05-19 | 学校法人慶應義塾 | 対象物の使用者を判定する方法 |
| GB2544481B (en) * | 2015-11-16 | 2019-12-11 | Century International Enterprises Ltd | A wearable article and a method for producing a wearable article |
| US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
| US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
| US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US12239706B2 (en) | 2015-11-30 | 2025-03-04 | Seed Health, Inc. | Method and system for protecting monarch butterflies from pesticides |
| US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
| EP3411011B1 (en) * | 2016-02-05 | 2024-09-18 | The Regents of the University of California | Compositions and methods for promoting skin health |
| US11504404B2 (en) | 2016-02-24 | 2022-11-22 | Crown Laboratories, Inc. | Skin probiotic formulation |
| KR20190017751A (ko) | 2016-04-21 | 2019-02-20 | 네이키드 바이옴, 인크. | 피부 장애의 치료를 위한 조성물 및 방법 |
| US20190336542A1 (en) * | 2016-04-21 | 2019-11-07 | Naked Biome, Inc. | Synthetic bacteria and methods of use |
| CA3022294A1 (en) * | 2016-04-25 | 2017-11-02 | uBiome, Inc. | Method and system for characterizing skin-related conditions |
| EP3243907A1 (en) * | 2016-05-13 | 2017-11-15 | Curetis GmbH | Stable pan-genomes and their use |
| WO2017200873A1 (en) | 2016-05-15 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating acne |
| CN106167820A (zh) * | 2016-05-19 | 2016-11-30 | 胤安国际（辽宁）基因科技股份有限公司 | 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用 |
| KR101961076B1 (ko) * | 2016-07-08 | 2019-03-21 | 카오카부시키가이샤 | 핵산 시료의 조제 방법 |
| CN113481294B (zh) * | 2016-07-08 | 2024-03-12 | 花王株式会社 | 核酸样品的制备方法 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| CA3040814A1 (en) * | 2016-10-19 | 2018-04-26 | S-Biomedic Nv | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
| JP6815006B2 (ja) | 2016-11-01 | 2021-01-20 | 株式会社桃谷順天館 | アクネ菌株選択的抗菌剤 |
| WO2018089337A1 (en) * | 2016-11-08 | 2018-05-17 | The Regents Of The University Of California | Compositions and methods for treating skin diseases and maintaining healthy skin |
| US11915795B2 (en) * | 2016-12-23 | 2024-02-27 | The Regents Of The University Of California | Method and device for digital high resolution melt |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165621A1 (en) | 2017-03-10 | 2018-09-13 | Prodermiq, Inc. | Customized skin care products and personal care products based on the analysis of skin flora |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| EP3612200A4 (en) * | 2017-04-21 | 2020-12-30 | Phi Therapeutics, Inc. | COMPOSITIONS CONTAINING BACTERIOPHAGES OF PROPIONIBACTERIUM ACNES INTENDED FOR THE TREATMENT OF ACNE |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019079612A1 (en) * | 2017-10-20 | 2019-04-25 | Naked Biome, Inc. | SYSTEMS AND METHODS OF BACTERIAL DETECTION AND TREATMENT |
| US20210177920A1 (en) * | 2017-12-05 | 2021-06-17 | Biomx Ltd. | Bacteriophage treatment for acne and biofilms |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020055547A2 (en) | 2018-08-18 | 2020-03-19 | Seed Health, Inc. | Methods and compositions for honey bee health |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US20220002782A1 (en) * | 2018-11-01 | 2022-01-06 | Kao Corporation | Method for preparing nucleic acid derived from skin cell of subject |
| KR102913696B1 (ko) * | 2018-11-16 | 2026-01-16 | 에스-바이오메딕 엔브이 | 산화 스트레스 관련 피부 질환 및 피부 노화의 치료 및 산화 스트레스 관련 피부 질환의 진단을 위한 조성물 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP3981012A4 (en) * | 2019-07-10 | 2023-07-19 | Jiang, Ruowei | SYSTEMS AND METHODS FOR PROCESSING IMAGES FOR SKIN ANALYSIS AND VISUALIZATION OF SKIN ANALYSIS |
| ES3004013T3 (en) * | 2019-07-12 | 2025-03-11 | Biomerieux Sa | Method for identification and epidemiological surveillance of a bacterial focus |
| US11578354B2 (en) | 2019-07-16 | 2023-02-14 | Meliolabs Inc. | Methods and devices for single-cell based digital high resolution melt |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021087415A1 (en) * | 2019-10-31 | 2021-05-06 | University Of Maryland, College Park | Method of treating infections by bacteriolytic enzymes and manufacture thereof |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CA3183350A1 (en) | 2020-06-23 | 2021-12-30 | Thomas M. Hitchcock | Probiotic skin formulations |
| KR20230159468A (ko) * | 2021-03-19 | 2023-11-21 | 패러렐 헬스, 인크. | 마이크로바이옴 식별 및 박테리오파지 제제 |
| CN113066533B (zh) * | 2021-04-02 | 2023-04-04 | 欧蒙医学诊断（中国）有限公司 | 一种mNGS病原体数据分析方法 |
| IL324411A (en) | 2023-05-05 | 2026-01-01 | Sanofi Pasteur Inc | Preparations for use in the treatment of acne |
| CN118737269B (zh) * | 2024-08-30 | 2024-11-19 | 墨卓生物科技(浙江)有限公司 | 在单细胞微生物基因组测序结果中区分菌株的方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670777B2 (en) | 1992-04-16 | 1996-08-01 | Ortho Pharmaceutical Corporation | Aqueous gel vehicles for retinoids |
| US5836999A (en) | 1995-09-28 | 1998-11-17 | Esc Medical Systems Ltd. | Method and apparatus for treating psoriasis using pulsed electromagnetic radiation |
| EP0895534A1 (en) | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| JPH11171783A (ja) | 1997-08-15 | 1999-06-29 | Vetoquinol Sa | 所定の動物に関して細胞性免疫と体重増加を生じる濃度でのバクテリアの経口投与 |
| EP1078104B1 (de) * | 1998-05-22 | 2002-10-09 | Creatogen Aktiengesellschaft | Nachweis von antibiotikumresistenzen in mikroorganismen |
| US6726913B1 (en) | 1999-10-15 | 2004-04-27 | The Van Kampen Group, Inc. | Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes |
| CA2407352A1 (en) | 2000-04-21 | 2001-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| WO2003033515A1 (en) * | 2001-10-15 | 2003-04-24 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
| US20040157837A1 (en) | 2002-11-07 | 2004-08-12 | Serbedzija George N. | Combinations for the treatment of fungal infections |
| NZ539076A (en) * | 2005-03-29 | 2008-05-30 | Blis Technologies Ltd | Skin treatment compositions |
| JP5127708B2 (ja) * | 2005-07-12 | 2013-01-23 | マイクレオス べスローテン フェンノートシャップ | バクテリオファージ及びその使用 |
| US20070269813A1 (en) | 2005-11-03 | 2007-11-22 | Dewhirst Floyd E | Methods and arrays for identifying human microflora |
| JP5201818B2 (ja) * | 2006-11-10 | 2013-06-05 | キヤノン株式会社 | プローブセット、プローブ固定担体及び遺伝子検査方法 |
| WO2009018447A2 (en) | 2007-07-31 | 2009-02-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
| EP2082736A1 (fr) * | 2008-01-23 | 2009-07-29 | Jean Hilaire Saurat | Composition pharmaceutique à usage topique |
| US20090269764A1 (en) * | 2008-02-19 | 2009-10-29 | Gen-Probe Incorporated | Compositions and methods for detection of propionibacterium acnes nucleic acid |
| CN102307562A (zh) | 2008-12-05 | 2012-01-04 | 加利福尼亚大学董事会 | 处理痤疮丙酸杆菌的方法和组合物 |
| US9457077B2 (en) * | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| MY167069A (en) * | 2010-05-27 | 2018-08-09 | Kenichiro Hasumi | Antigen peptide and use thereof |
| EP3692999A1 (en) * | 2012-03-17 | 2020-08-12 | The Regents of the University of California | Fast diagnosis and personalized treatments for acne |
| EP2664919A1 (fr) * | 2012-05-15 | 2013-11-20 | Jean Hilaire Saurat | Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique |
| EP2885421A1 (en) * | 2012-07-13 | 2015-06-24 | L'Oréal SA | Method of in vitro diagnosing a pellicular state in a subject and related applications |
| MX2015001751A (es) | 2012-08-07 | 2015-11-13 | Topgenix Inc | Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes. |
| US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| AU2014212004B2 (en) * | 2013-02-04 | 2018-09-20 | Société des Produits Nestlé S.A. | Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases |
| KR102611070B1 (ko) * | 2013-11-25 | 2023-12-07 | 세레스 테라퓨틱스, 인코포레이티드 | 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도 |
| US9737592B1 (en) * | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| EP3139939B1 (en) | 2014-05-07 | 2023-09-06 | The Regents of The University of California | Compositions and methods for treating skin and mucous membrane diseases |
| CA2950945A1 (en) * | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
| WO2017023680A1 (en) * | 2015-07-31 | 2017-02-09 | The Regents Of The University Of California | Mycobacterium lysterase: a novel treatment for acne |
| EP3411011B1 (en) * | 2016-02-05 | 2024-09-18 | The Regents of the University of California | Compositions and methods for promoting skin health |
| KR20190017751A (ko) * | 2016-04-21 | 2019-02-20 | 네이키드 바이옴, 인크. | 피부 장애의 치료를 위한 조성물 및 방법 |
| WO2017200873A1 (en) * | 2016-05-15 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating acne |
| CA3040814A1 (en) * | 2016-10-19 | 2018-04-26 | S-Biomedic Nv | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
| US20210177920A1 (en) * | 2017-12-05 | 2021-06-17 | Biomx Ltd. | Bacteriophage treatment for acne and biofilms |
| CA3183350A1 (en) * | 2020-06-23 | 2021-12-30 | Thomas M. Hitchcock | Probiotic skin formulations |
-
2013
- 2013-03-15 EP EP19218444.8A patent/EP3692999A1/en not_active Withdrawn
- 2013-03-15 SG SG11201405783VA patent/SG11201405783VA/en unknown
- 2013-03-15 JP JP2015501822A patent/JP2015512255A/ja not_active Withdrawn
- 2013-03-15 CN CN201910052894.1A patent/CN110055320A/zh active Pending
- 2013-03-15 US US14/385,576 patent/US20150086581A1/en not_active Abandoned
- 2013-03-15 CA CA2867621A patent/CA2867621A1/en not_active Abandoned
- 2013-03-15 CN CN201380025853.4A patent/CN104364394B/zh not_active Expired - Fee Related
- 2013-03-15 AU AU2013235340A patent/AU2013235340B2/en not_active Ceased
- 2013-03-15 BR BR112014023005A patent/BR112014023005A2/pt not_active Application Discontinuation
- 2013-03-15 WO PCT/US2013/032551 patent/WO2013142378A1/en not_active Ceased
- 2013-03-15 EP EP13764219.5A patent/EP2825676B1/en not_active Not-in-force
- 2013-03-15 EP EP17002012.7A patent/EP3360560A1/en not_active Withdrawn
-
2016
- 2016-09-06 US US15/257,423 patent/US10364473B2/en active Active
-
2019
- 2019-01-10 JP JP2019002573A patent/JP2019050833A/ja active Pending
- 2019-04-22 US US16/390,575 patent/US20190316183A1/en not_active Abandoned
- 2019-08-22 AU AU2019219817A patent/AU2019219817A1/en not_active Abandoned
-
2020
- 2020-09-02 AU AU2020227049A patent/AU2020227049A1/en not_active Abandoned
- 2020-09-25 US US17/033,034 patent/US11692229B2/en active Active
- 2020-11-12 JP JP2020188630A patent/JP2021013395A/ja active Pending
-
2023
- 2023-06-30 US US18/217,206 patent/US20240117446A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021016347A1 (en) * | 2019-07-22 | 2021-01-28 | The Regents Of The University Of California | Compositions and methods for treating skin infections and other diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013235340A1 (en) | 2014-10-16 |
| US20170058328A1 (en) | 2017-03-02 |
| EP3692999A1 (en) | 2020-08-12 |
| JP2019050833A (ja) | 2019-04-04 |
| CN104364394B (zh) | 2019-02-22 |
| US20190316183A1 (en) | 2019-10-17 |
| WO2013142378A1 (en) | 2013-09-26 |
| US20240117446A1 (en) | 2024-04-11 |
| EP2825676A1 (en) | 2015-01-21 |
| WO2013142378A9 (en) | 2014-01-23 |
| CN104364394A (zh) | 2015-02-18 |
| BR112014023005A2 (pt) | 2017-07-18 |
| AU2020227049A1 (en) | 2020-09-17 |
| AU2013235340B2 (en) | 2019-05-23 |
| AU2019219817A1 (en) | 2019-09-12 |
| JP2015512255A (ja) | 2015-04-27 |
| US10364473B2 (en) | 2019-07-30 |
| CN110055320A (zh) | 2019-07-26 |
| EP3360560A1 (en) | 2018-08-15 |
| EP2825676B1 (en) | 2017-12-20 |
| EP2825676A4 (en) | 2015-09-30 |
| US11692229B2 (en) | 2023-07-04 |
| SG11201405783VA (en) | 2014-10-30 |
| JP2021013395A (ja) | 2021-02-12 |
| HK1207402A1 (en) | 2016-01-29 |
| US20210123092A1 (en) | 2021-04-29 |
| US20150086581A1 (en) | 2015-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240117446A1 (en) | Fast diagnosis and personalized treatments for acne | |
| Fittipaldi et al. | Full-genome dissection of an epidemic of severe invasive disease caused by a hypervirulent, recently emerged clone of group A Streptococcus | |
| Liu et al. | The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin | |
| Chaguza et al. | Mechanisms and impact of genetic recombination in the evolution of Streptococcus pneumoniae | |
| Meehan et al. | Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching | |
| Lu et al. | Comparative analysis of the full genome of Helicobacter pylori isolate Sahul64 identifies genes of high divergence | |
| Howell et al. | The use of genome wide association methods to investigate pathogenicity, population structure and serovar in Haemophilus parasuis | |
| Tokajian et al. | Molecular characterization of Staphylococcus aureus in Lebanon | |
| Schindler et al. | Group B streptococcus virulence factors associated with different clinical syndromes: Asymptomatic carriage in pregnant women and early-onset disease in the newborn | |
| HK40011589A (en) | Fast diagnosis and personalized treatments for acne | |
| Speck et al. | Characterization of Streptococcus equi subsp. ruminatorum isolated from spotted hyenas (Crocuta crocuta) and plains zebras (Equus burchelli), and identification of a M-like protein (SrM) encoding gene | |
| HK1207402B (zh) | 痤疮的快速诊断和个体化治疗 | |
| Khan | Detailed genomic and antimicrobial resistance comparison of UK Streptococcus agalactiae isolates from adults to those of diverse global origins | |
| JP2009515525A (ja) | Ｕｓａ３００市中感染メチシリン−耐性黄色ブドウ球菌の同定 | |
| Schiff | The Bacterial and Viral Complexity of Postinfectious Hydrocephalus in Uganda | |
| Alexander | Using Whole Genome Sequencing to Study the Epidemiology and Comparative Genomics of Streptococcus equi from the United States | |
| Watkins et al. | 233. The Epidemiology, Genomics, and Evolution of Staphylococcus aureus in Northeast Ohio | |
| Mir et al. | Research Article Supershed Escherichia coli O157: H7 Has Potential for Increased Persistence on the Rectoanal Junction Squamous Epithelial Cells and Antibiotic Resistance | |
| Gill | Evolutionary drivers of the rise and fall of a dominant hybrid MRSA, ST239 | |
| Muhamed | The molecular characterisation of Group A Streptococcus among children with phyryngitis in the Vanguard community (Bonteheuwel | |
| Roussado et al. | Streptococcus agalactiae in neonatal infections–a changing population? | |
| Proud | Examining the Role of Transformation in the Acquisition of Resistance and Rescue of Genomes from Oxidative Stress | |
| Moloney | Molecular typing of Irish Streptococcus equi ssp equi strains | |
| Cohen et al. | I nt er na t io nal Jo ur na l of Infectious Diseases | |
| Zdziarski et al. | Host Imprints on Bacterial Genomes—Rapid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180314 |
|
| FZDE | Discontinued |
Effective date: 20210831 |